Currently, there is limited evidence on the safety and efficacy of intermittent dosing strategies, and the consensus among obesity specialists is that this approach is not generally advised except in specific clinical scenarios under close supervision
Placebo-controlled trials are critical to demonstrate that the drug is effective and safe and not just better than nothing
But in a context where coverage of GLP-1s is not required, (although in a recent column it was proposed that anti-obesity medications should be considered preventive by the US Preventive Services Task Force) an insurer might fear adverse selection if they covered the medications while their competitors did not
PlexusDx operates in all 50 states with no insurance required, but serious cardiac symptoms always supersede telemedicine carevisit an emergency department if symptoms are severe
What you need to know, Harvard Health Publishing (2024) FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize, Food and Drug Administration (2025) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
Red Flags When Evaluating a Peptide Vendor The FDA's 2025 and 2026 enforcement actions targeted suppliers whose labeling or website language implied human use, suggested therapeutic effects, or marketed the compound by comparison to FDA-approved drugs
